Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PLTR topped the analyst action table today. The consensus rating was upgraded, with the average target price rising to $200.88 from $199.84. The stock carries a market cap above $446 billion. Short interest sits at just 2.7% of free float, leaving little ammunition for bears.
VLO saw the sharpest target price move among energy names. Analysts lifted the average target to $387.05 from $380.00, a gain of more than $7. The refiner's consensus holds two buy ratings against nine holds.
PCAR moved in the opposite direction. The consensus target slipped to $140.06 from $141.44. Japan machine tool orders surged 65% year-on-year in August 2026, per ORTEX alt data, a signal that industrial capex is running hot. That backdrop may explain why analysts are still cautious on truck-maker valuations even as demand indicators improve.
also picked up a small target increase, to $280.96 from $280.79. ORTEX alt data shows trial completion date slippage for AbbVie running 2.1 standard deviations below its own history, meaning trials are completing faster than normal. That is an unusual positive read for a pharma pipeline.
CRWD rounded out the notable movers. The cybersecurity firm saw its consensus target rise to $238.97 from $237.77, backed by 37 buy ratings against 13 holds.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
